Acura shares plunge 36% on Pfizer termination of opioid license deal
This article was originally published in Scrip
Acura Pharmaceuticals' share price fell 36.4% when the stock market had its first chance to react to news announced late on 27 July that Pfizer will terminate its license for three pre-commercial drug candidates developed by the specialty pain therapeutics company, but the partners will continue their relationship for the marketed drug Oxecta (oxycodone hydrochloride).
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.